Archives of Alzheimer's & Parkinson's Disease

Chen, Arch Alzheimers Parkinsons Dis. 2024;1(1):1-3.

Editorial

Fronting the twin challenges: Alzheimer's and Parkinson's disease

Chong Chen[1,*]

[1]School of Life Science, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi, PR China

*Author for correspondence: Email: FrankeeeeChan@outlook.com

Received date: September 09, 2023
Accepted date: October 21, 2024

Introduction

Alzheimer's and Parkinson's diseases are two of the most prominent and complex progressive neurological disorders that have a profound global impact [1,2]. These diseases affect millions of individuals worldwide, causing significant morbidity and placing a substantial burden on healthcare systems and society [3,6]. Despite considerable advancements in understanding these disorders over the years, developing effective treatments remains a complex and multifaceted challenge [7,8]. This editorial aims to comprehensively examine the current state of research and treatment of Alzheimer's and Parkinson's diseases. By highlighting the areas of progress and the challenges that persist, we emphasize the critical need for advanced therapeutic strategies to address these debilitating conditions.

Understanding Alzheimer's and Parkinson's Diseases

Alzheimer's disease (AD) and Parkinson's disease (PD) are both characterized by neuronal degeneration, although this occurs in distinct regions of the brain [9-11]. In AD, the accumulation of amyloid-beta plaques and tau protein tangles primarily affects memory and cognitive functions. The accumulation of these abnormal protein deposits in the brain interferes with the normal functioning of neurons, resulting in a progressive deterioration of cognitive functions, including memory, language, and problem-solving skills. Conversely, in PD, the loss of dopamine-producing neurons in the substantia nigra impairs motor skills [12,13]. This results in symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. The degeneration of these specific neurons leads to a deficiency in dopamine, a neurotransmitter crucial for fluid and coordinated movement [14,15]. Notably, both AD and PD exhibit overlapping symptomatology, suggesting interconnected pathophysiological mechanisms. For instance, some patients with AD may also develop motor symptoms similar to those observed in PD, and vice versa. This overlap indicates that there may be common underlying factors contributing to the development and progression of these diseases, such as oxidative stress, inflammation, and mitochondrial dysfunction [16-18].

Recent Advances in Research

The recent decade has witnessed a significant increase in biomarker research aimed at the initial detection and monitoring of disease progression in AD and PD. Advanced imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), have enabled researchers to identify changes in the brain years before the manifestation of symptoms. These imaging modalities can detect the presence of amyloid plaques, tau tangles, and dopamine deficits [19], providing valuable insights into the early stages of disease development. In addition to imaging

biomarkers, fluid biomarkers have also emerged as efficacious tools for early detection. Biomarkers such as amyloid-beta and tau proteins in cerebrospinal fluid (CSF) and blood can indicate the presence of AD and PD even before symptoms appear [20,21]. These biomarkers can also help monitor disease progression and response to treatment. Research has also focused on elucidating the genetic foundations of AD and PD. Studies have revealed numerous risk genes that increase the likelihood of developing these diseases. For example, the APOE ε4 allele is a well-established risk factor for AD [22], while mutations in the LRRK2 gene are associated with an increased risk of PD [23]. Understanding these genetic risk factors has presented new opportunities for targeted gene therapies.

Challenges in Current Treatment Regimens

Current treatments for AD and PD predominantly focus on symptom management rather than disease modification. In AD, cholinesterase inhibitors and memantine are commonly used to maintain cognitive function [24,25]. These medications function by increasing the levels of neurotransmitters in the brain or inhibiting the breakdown of existing neurotransmitters. However, they do not halt the progression of the disease. Similarly, in PD, therapies mainly concentrate on replenishing dopamine levels. Medications such as levodopa and dopamine agonists can ameliorate motor symptoms, though they do not address the fundamental neurodegenerative process [26,27]. Furthermore, extended use of these medications can contribute to the development of adverse effects such as dyskinesias, which are characterized by abnormal involuntary movements, as well as inconsistencies in symptom control [28]. The development of disease-modifying therapies has been fraught with challenges. The complex and multifaceted nature of Alzheimer's disease and Parkinson's disease presents difficulties in identifying a singular treatment mechanism. These diseases involve a combination of genetic, environmental, and lifestyle factors, as well as multiple pathophysiological processes including protein misfolding, inflammation, and oxidative stress.

Innovative Approaches in Therapy

Recent years have witnessed promising advancements in immunotherapy approaches for neurodegenerative diseases. Immunotherapy aims to eliminate pathological proteins in the brain through immune system stimulation [29,30]. Clinical trials investigating vaccines against amyloid-beta and tau proteins in AD and alpha-synuclein in PD have demonstrated potential [31,32]. These vaccines function by eliciting an immune response against specific pathological proteins, resulting in their elimination from the brain. In addition to immunotherapy, stem cell therapy presents regenerative possibilities. Stem cells possess the capacity to differentiate into neurons and replace lost cells in the brain [33,34]. Ongoing research seeks to determine the safety and efficacy of stem cell therapy in AD and PD. If successful, this approach could potentially restore neurological function and decelerate disease progression.

The Role of Technology and AI

Artificial Intelligence (AI) is transforming the field of neurodegenerative diseases. AI has the potential to enhance diagnostic accuracy through the analysis of large volumes of medical data, including imaging scans and biomarker results. Machine learning models can identify patterns and predict disease progression and outcomes, thereby facilitating personalized treatment plans [35,36]. Digital health tools are also improving patients' quality of life. These tools can assist in medication management, and symptom monitoring, and provide support and education to patients and caregivers. For instance, wearable devices can track movement and activity levels, while mobile applications can aid patients in managing their medications and scheduling appointments [37,38].

Future Directions

Looking ahead, the integration of interdisciplinary research is imperative. Neurology, genetics, immunology, and computational sciences must collaborate to gain a deeper understanding of AD and PD. Collaborative international efforts and increased funding are essential to accelerate the pace of discovery and clinical applications. Public awareness and education regarding these diseases will also play a critical role. Early diagnosis is crucial for effective treatment, and reducing stigma can encourage patients to seek assistance and participate in research [39,40]. By raising awareness about AD and PD, we can mobilize communities to support research and improve the lives of those affected.

Conclusion

Alzheimer's and Parkinson's diseases represent not only a significant challenge to the scientific community but also necessitate a reevaluation of approaches to mental health and elder care. As research continues to progress, there is optimism that the coming years will bring about breakthroughs that can transform the lives of those affected by neurodegenerative diseases. Through innovative therapeutic approaches, the integration of technology and AI, and increased public awareness, we can strive towards finding effective treatments and improving the quality of life for millions of individuals worldwide.

References

1. Balestrino R, Schapira AH. Parkinson disease. European Journal of Neurology. 2020 Jan;27(1):27-42.
2. Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nature Reviews Disease Primers. 2021 May 13;7(1):33.
3. Grabher BJ. Effects of Alzheimer disease on patients and their family. Journal of Nuclear Medicine Technology. 2018 Dec 1;46(4):335-40.
4. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. Doctoral dissertation, Alzheimer's Disease International.
5. Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs & Aging. 2006 Sep;23:693-721.
6. Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. American Journal of Health-System Pharmacy. 2000 May 15;57(10):953-62.
7. Castellani RJ, Perry G. The complexities of the pathology–pathogenesis relationship in Alzheimer disease. Biochemical Pharmacology. 2014 Apr 15;88(4):671-6.
8. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Archives of Neurology. 2005 Mar 1;62(3):353-7.

9. Dickson DW. Neuropathology of Parkinson disease. Parkinsonism & Related Disorders. 2018 Jan 1;46:S30-3.

10. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Annals of the New York Academy of Sciences. 1999 Nov;893(1):154-75.

11. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Progress in Neurobiology. 2000 Feb 1;60(2):139-65.

12. Paula VD, Guimarães FM, Diniz BS, Forlenza OV. Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?. Dementia & Neuropsychologia. 2009;3(3):188-94.

13. Roda AR, Serra-Mir G, Montoliu-Gaya L, Tiessler L, Villegas S. Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease. Neural Regeneration Research. 2022 Aug 1;17(8):1666-74.

14. Bologna M, Guerra A, Colella D, Cioffi E, Paparella G, Di Vita A, et al. Bradykinesia in Alzheimer's disease and its neurophysiological substrates. Clinical Neurophysiology. 2020 Apr 1;131(4):850-8.

15. Reinikainen KJ, Paljarvi L, Halonen T, Malminen O, Kosma VM, Laakso M, et al. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiology of Aging. 1988 Jan 1;9:245-52.

16. Alam Q, Zubair Alam M, Mushtaq G, A Damanhouri G, Rasool M, Amjad Kamal M, et al. Inflammatory process in Alzheimer's and Parkinson's diseases: central role of cytokines. Current Pharmaceutical Design. 2016 Feb 1;22(5):541-8.

17. Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Design, Development and Therapy. 2017 Mar 16:797-810.

18. Jiang T, Sun Q, Chen S. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease. Progress in Neurobiology. 2016 Dec 1;147:1-9.

19. Burkett BJ, Johnson DR, Lowe VJ. Evaluation of Neurodegenerative Disorders with Amyloid-β, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls. Journal of Nuclear Medicine. 2024 Jun 1;65(6):829-37.

20. Lue LF, Guerra A, Walker DG. Amyloid beta and tau as Alzheimer's disease blood biomarkers: promise from new technologies. Neurology and Therapy. 2017 Jul;6:25-36.

21. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007 Feb 27;68(9):666-9.

22. Michaelson DM. APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimer's & Dementia. 2014 Nov 1;10(6):861-8.

23. Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nature Reviews Neurology. 2020 Feb;16(2):97-107.

24. Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer's disease: an updated systematic review and meta-analysis. Journal of Alzheimer's Disease. 2017 Jan 1;60(2):401-25.

25. Sharma K. Cholinesterase inhibitors as Alzheimer's therapeutics. Molecular Medicine Reports. 2019 Aug 1;20(2):1479-87.

26. LeWitt PA. Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics. Movement Disorders. 2015 Jan;30(1):64-72.

27. Yamamoto M, Schapira AH. Dopamine agonists in Parkinson's disease. Expert Review of Neurotherapeutics. 2008 Apr 1;8(4):671-7.

28. YY Szeto J, JG Lewis S. Current treatment options for Alzheimer's disease and Parkinson's disease dementia. Current Neuropharmacology. 2016 May 1;14(4):326-38.

29. Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, et al. Immunotherapy for Alzheimer's disease: Targeting β-amyloid and beyond. Translational neurodegeneration. 2022 Mar 18;11(1):18.

30. Schwab AD, Thurston MJ, Machhi J, Olson KE, Namminga KL, Gendelman HE, et al. Immunotherapy for Parkinson's disease. Neurobiology of disease. 2020 Apr 1;137:104760.

31. Mantile F, Prisco A. Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer's Disease. Biology. 2020 Nov 27;9(12):425.

32. Fleming SM, Davis A, Simons E. Targeting alpha-synuclein via the immune system in Parkinson's disease: current vaccine therapies. Neuropharmacology. 2022 Jan 1;202:108870.

33. Liu XY, Yang LP, Zhao L. Stem cell therapy for Alzheimer's disease. World Journal of Stem Cells. 2020 Aug 8;12(8):787.

34. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Medicine. 2012 Dec;10:1-7.

35. Raghavendra U, Acharya UR, Adeli H. Artificial intelligence techniques for automated diagnosis of neurological disorders. European Neurology. 2020 Nov 19;82(1-3):41-64.

36. Zhang J, Zhang X, Sh Y, Liu B, Hu Z. Diagnostic AI Modeling and Pseudo Time Series Profiling of AD and PD Based on Individualized Serum Proteome Data. Frontiers in Bioinformatics. 2021 Oct 22;1:764497.

37. Kourtis LC, Regele OB, Wright JM, Jones GB. Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity. NPJ Digital Medicine. 2019 Feb 21;2(1):9.

38. Pasluosta CF, Gassner H, Winkler J, Klucken J, Eskofier BM. An Emerging Era in the Management of Parkinson's Disease: Wearable Technologies and the Internet of Things. IEEE J Biomed Health Inform. 2015 Nov;19(6):1873-81.

39. Bacsu JD, Johnson S, O'Connell ME, Viger M, Muhajarine N, Hackett P, et al. Stigma Reduction Interventions of Dementia: A Scoping Review. Can J Aging. 2022 Jun;41(2):203-13.

40. Henry RS, Perrin PB, Lageman SK, Villaseñor T, Cariello AN, Pugh M, et al. Parkinson's Symptoms and Caregiver Affiliate Stigma: A Multinational Study. Curr Alzheimer Res. 2021;18(3):222-31.